CarelonRx will add Humira biosimilar drugs to its commercial formularies on December 1, 2023.
Adalimumab-adbm (lower list price version) will be added to all CarelonRx commercial formularies. Cyltezo will be added to select commercial formularies. Both will be at parity with Humira. These biosimilar alternatives to Humira, the top-selling drug in the United States for more than a decade, will offer more treatment choices for members with inflammatory conditions and increased cost management opportunities for plan sponsors.
Biosimilar drugs are biological products that are highly similar and have no clinically meaningful difference from the existing FDA-approved product. The biosimilar drugs will be less expensive than Humira. Lower cost options may ultimately lead to greater medication adherence by members and help contribute to health equity.
Cyltezo and adalimumab-adbm are the first biosimilars to receive an interchangeable designation by the FDA. CarelonRx will continue to keep Humira on its commercial formularies to provide our members and providers with a choice. Commercial members may also be able to take advantage of manufacturer sponsored patient copay assistance programs available for Humira and the biosimilar drugs.
CarelonRx is actively negotiating to achieve the lowest costs on more biosimilar drugs.
Please contact your Anthem representative for more information.